CRISPR / Cas-based diagnostics and gene therapy

0

Announcement of a new article publication for Organic integration newspaper. In this mini review article, authors Meiyu Qiu and Pei Li from Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea summarize CRISPR / Cas-based Diagnostics and Gene Therapy.

CRISPR (Short Palindromic Repeats Regularly Spaced In Clusters) technology, a simple, fast, cost-effective and accurate gene editing technique, has revolutionized gene therapy and diagnostics. Rapid and accurate disease diagnosis is essential for point-of-care testing (POCT) and specialist medical institutes. The CRISPR associated protein system (Cas) has brought to light new methods of point-of-care (POC) diagnostics, due to its advantages. In addition, CRISPR / Cas based gene editing technology has led to various breakthroughs in the field of gene therapy. It has been used in clinical trials for a variety of incurable diseases, including cancer, blood disorders, and other syndromes. Currently, the clinical application of CRISPR / Cas has mainly focused on ex vivo therapies.

Recently, enormous efforts have been made in the development of an ex vivo gene therapy based on CRISPR-Cas9. Despite these efforts, in vivo CRISPR / Cas gene therapy is still in its early stages. In this review, the authors discuss milestones in CRISPR / Cas technologies that advance the field of diagnostics and gene therapy. Recent advances in diagnosis and gene therapy based on CRISPR / Cas technology are highlighted and the strength and significant challenges of CRISPR / Cas technology for its future clinical use in diagnosis and gene therapy are discussed.

Article reference: Meiyu Qiu and Pei Li, CRISPR / Cas-based Diagnostics and Gene Therapy. Organic integration, 2021, https: //do I.org /ten.15212 /bioi-2020-0048

Organic integration is an open-access journal that will enable the rapid dissemination of multidisciplinary perspectives on advances in modern medicine.

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and waiving copyright fees during its sessions. first years. In addition, publication support for authors whose native language is not English will be offered in areas such as manuscript development, English editing and assistance with illustrations.

###

BIOI is now open for submissions; articles can be submitted online at:

https: //mc04.manuscriptcentral.com /bioi

Please visit http: // www.bio-integration.org to learn more about the newspaper.

Editorial board: https: //bio-integration.org /Editorial board /

Please visit http: // www.bio-integration.org to learn more about the newspaper.

Editorial board: https: //bio-integration.org /Editorial board /

BIOI is available on the IngentaConnect platform (https: //www.ingentaconnect.com /content /cscript /bioi) and at Organic integration website (http: // www.bio-integration.org).

Submissions can be made using ScholarOne (https: //mc04.manuscriptcentral.com /bioi).

There are no author submission or article processing fees.

Follow BIOI on Twitter @JournalBio; Facebook (https: //www.Facebook.com /BIO-Integration-Journal-108140854107716 /) and LinkedIn (https: //www.LinkedIn.com /business/bio-integration-journal /).

ISSN 2712-0074

eISSN 2712-0082

Keywords: Clinical trials, CRISPR / Case, diagnosis, gene therapy, point-of-care testing.

Warning: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.

Source link

Leave A Reply

Your email address will not be published.